Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a novel drug class that will help fulfill the need for additional therapies. Currently, physicians are limited to iron supplements and erythropoietin-stimulating agents (ESAs), which, although effective, have drawbacks. The hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected to launch during the study period and appear to be able to effectively, safely, and conveniently improve renal anemia. However, to succeed, these novel therapies will have to convince physicians and payers of their safety and efficacy benefits compared with current therapies. In addition, HIF-PH inhibitors will face other major challenges, such as reimbursement hurdles, the availability of biosimilar ESAs, and an increasingly stringent regulatory environment. Despite the promise of the HIF-PH inhibitors, the late-phase renal anemia pipeline is relatively weak; only iron supplement-based technologies are approaching market entry.
QUESTIONS ANSWERED
What opportunities exist for the marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors, due to the CV issues associated with current therapies?
With the imminent availability of biosimilars in the United States, will emerging therapies offering only incremental improvements over existing therapies struggle?
What do key opinion leaders think about iron-based phosphate binders for the treatment of renal anemia?
PRODUCT DESCRIPTION
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.